CytoSorbents

CYTOSORBENTS CORP

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

BZ_briefs

Equities

News

Small Cap

Movers

CTSO

CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device.

Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth

vaccine-4892048

CytoSorbents shares are trading higher by 20% during Tuesday&#39;s session. The company entered into a new $20 million credit facility with Avenue Capital Group.

Why CytoSorbents (CTSO) Stock Is Trading Higher

Earnings

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

BJDX

CING

DOYU

MBOT

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday.

The Dow traded up 0.27% to 37,758.26 while the NASDAQ rose 0.17% to 15,124.90. The S&amp;P 500 also rose, gaining, 0.23% to 4,792.56.

Gold Moves Lower; US Crude Stocks Decline Last Week

CytoSorbents Corp

Offerings

Press Releases

CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

CytoSorbents to Participate at the Jefferies Global Healthcare Conference

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

Apyx Medical

HeartBeam

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Edap TMS

Femasys

Fonar

Fractyl Health

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

Hyperfine

Pulmonx

Microbot Medical

Monogram Technologies Inc. - Common Stock

Monogram Technologies

Milestone Scientific

Modular Medical

Myomo

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Tech

enVVeno Medical Corporation - Common Stock

enVVeno Medical

Odysight ai

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Sensus Healthcare

Vivani Medical

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International

Zynex

D. Boral Capital

HC Wainwright & Co.

EF Hutton

B. Riley Securities

Comments

CytoSorbents

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell